Bevacizumab, bleeding, thrombosis, and warfarin

J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543. doi: 10.1200/JCO.2003.99.046.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / pathology*
  • Endothelial Growth Factors / immunology*
  • Fluorouracil / administration & dosage
  • Hemorrhage / chemically induced*
  • Humans
  • Intercellular Signaling Peptides and Proteins / immunology*
  • Leucovorin / administration & dosage
  • Lymphokines / immunology*
  • Neoplasm Metastasis
  • Thrombosis / chemically induced*
  • Thrombosis / prevention & control*
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Warfarin / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Endothelial Growth Factors
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Bevacizumab
  • Warfarin
  • Leucovorin
  • Fluorouracil